STUDY 2: Breast Cancer Recurrence

Detailed Study Description

About 1 in 8 U.S. women (about 12%) will develop invasive breast cancer over the course of her lifetime. In 2019, an estimated 268,600 new cases of invasive breast cancer are expected to be diagnosed in women in the U.S., along with 62,930 new cases of non-invasive (in situ) breast cancer. The Agency for Healthcare research and Quality (AHRQ) estimates that the direct medical costs (total of all health care costs) for all types of cancer in the US in 2015 were $80.2 billion. This year, about 609,640 Americans are expected to die of cancer – that’s more than 1,670 people a day. Cancer is the second most common cause of death in the US, exceeded only by heart disease.

The VIDA Center (Santa Teresa, Costa Rica) employs a novel approach of combining several evidence based adjunct therapies in the treatment of cancer. Through the combination of several Diet and Lifestyle Interventions, improved sleep, and psychosocial support strategies, participants are educated and challenged to eliminate behaviors and environmental exposures that are considered high risk, correlative or even likely causative to the development of cancer. Participants receive 12 weeks of high touch health coaching and attend 3 weeks at a wellness center located in Costa Rica. This approach avoids pharmacological treatment and allows for a reproducible methods with achievable ‘at home’ adherence compared to existing non conventional treatments.

The VIDA Center therapeutic system consists of a proprietary program that applies 7 distinctive, yet interconnected Epigenetic therapies (changes that affect gene activity and expression). These non toxic therapies appear to support the human body’s natural ability to manage a variety of diseases including cancer. The 7 therapies incorporate nutrigenomics, microbiomics, lifestyle stress reduction, exercise, social support, and emotional wellbeing. The application of these therapies has been effective in individual patient treatment. For the purposes of this study, the investigators will be using all seven therapies in a small group setting, over a fixed period of time. Participants will measured for a wide variety of health and cancer markers at the beginning and at the end of the 12 week program.

Study Type: Practice Based Observational

Estimated Enrollment: 10 participants

Official Title: Effect of Diet and Lifestyle Interventions on Recurrent Breast Cancer

General Inclusion: Recent diagnosis of recurrent Breast Cancer, all ages, Stages I & II (some stage 3 cases may be accepted), medically stable. Women only.

General Exclusion: High degree of difficulty with pain management, medical complications requiring hospital environment.

Actual Study Start Date: October 1st, 2019

Estimated Primary Completion Date: January 30th, 2019

Estimated Study Completion Date: March 15, 2020 

Sponsor:

VIDA Research

Collaborators:

Sanjevani Integrative Medicine Health and Lifestyle Center

VIDA Center

Information provided by (Responsible Party):

VIDA Research

(this link takes to a secure form. it will

ASK FOR YOUR NAME AND EMAIL FIRST)